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Abstract: The goal of this study was to investigate whether certain metabolites, specific 
to neurons, glial cells, and the neuronal-glial neurotransmission system, in the primary 
somatosensory cortex (SSC), are altered and correlated with clinical characteristics of pain 
in patients with chronic low back pain (LBP). Eleven LBP patients and eleven age-matched 
healthy controls were included. N-acetylaspartate (NAA), choline (Cho), myo-inositol (mI), 
and glutamine/glutamate (Glx) were measured with proton magnetic resonance spectroscopy 
(1H-MRS) in left and right SSC. Differences in metabolite concentrations relative to those of 
controls were evaluated as well as analyses of metabolite correlations within and between SSCs. 
Relationships between metabolite concentrations and pain characteristics were also evaluated. 
We found decreased NAA in the left SSC (P = 0.001) and decreased Cho (P = 0.04) along 
with lower correlations between all metabolites in right SSC (P = 0.007) in LBP compared to 
controls. In addition, we found higher and significant correlations between left and right mI 
(P , 0.001 in LBP vs P = 0.1 in controls) and between left mI and right Cho (P = 0.048 vs P = 
0.6). Left and right NAA levels were negatively correlated with pain duration (P = 0.04 and 
P = 0.02 respectively) while right Glx was positively correlated with pain severity (P = 0.04). 
Our preliminary results demonstrated significant altered neuronal-glial interactions in SSC, 
with left neural alterations related to pain duration and right neuronal-glial alterations to pain 
severity. Thus, the 1H-MRS approach proposed here can be used to quantify relevant cerebral 
metabolite changes in chronic pain, and consequently increase our knowledge of the factors 
leading from these changes to clinical outcomes.
Keywords: chronic low back pain, primary somatosensory cortex, magnetic resonance 
spectroscopy, neuronal-glial interactions
Introduction
The most prevalent and debilitating chronic pain condition is low back pain (LBP), 
affecting 85% of adults in US.1 Chronic LBP, defined by the presence of pain for longer 
than 3 months, is associated with significant physical and psychological disability that 
results in work absenteeism and economic burden, costing $86 billion annually.2–4 
Since the spinal imaging findings are poorly correlated with clinical characteristics of 
pain,5 brain imaging studies6–9 have attempted to gain a better understanding of pain 
neurobiology. Recently, the spectacular development of imaging techniques10–12 has 
improved this understanding even more.
Accumulating evidence suggests that chronic pain is due to central nervous 
system changes.6 Specifically, animal studies have shown spinal13,14 and cortical15,16 
sensitization in various chronic pain conditions. Human imaging studies have also Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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revealed pathophysiological changes in brain regions 
involved in both affective-motivational and sensorial aspects 
of pain processing in chronic LBP. For instance, proton 
magnetic resonance spectroscopy (1H-MRS) studies have 
shown low N-acetylaspartate (NAA), a marker of neuronal 
integrity,17,18 in the dorsolateral prefrontal cortex (DLPFC), 
anterior cingulate cortex (ACC) and anterior insula in 
chronic LBP.7–9 Further, low NAA in the DLPFC has been 
correlated with pain severity and associated symptoms, such 
as anxiety and depression.7,9 Another 1H-MRS metabolite, 
myo-inositol (mI), a glial marker,18 was also decreased 
in the ACC and thalamus.10 Finally, glutamate, the major 
brain excitatory neurotransmitter, was also decreased in the 
ACC.10 Taken together, these studies suggested alterations 
of neuronal-glial interactions in brain regions involved in 
the affective-motivational aspect of pain. No such studies 
have been reported that relate to the primary somatosensory 
cortex (SSC), a major cortical region involved in sensory-
discrimination and nociception integration.
Here, we focus on the SSC, as an extensive reorganization 
of this area has been reported in chronic LBP. Specifically, 
an increased activity and an expansion of the back corti-
cal representation into leg and foot representations19 were 
reported in these patients. This finding was also confirmed 
in people with high catastrophic behavior (illness behavior) 
and positive Waddell signs following chronic LBP.20 Further 
evidence comes from morphometric studies that showed a 
decrease in the SSC gray matter volume in chronic LBP.21
These SSC functional/morphometric changes are probably 
accompanied by chemical alterations. Therefore, the goals of 
the present study were (i) to determine whether 1H-MRS-
visible metabolites specific to neuronal-glial interactions are 
altered within the SSC in chronic LBP; and (ii) to investigate 
whether changes in these metabolites relate to clinical level of 
pain. Based on the essential role of neuronal-glial interactions 
in extracellular ionic homeostasis, neurotransmission and 
ultimately in neuronal function,18 we analyzed the following 
metabolites: NAA; choline (Cho), reflecting cell membrane 
integrity; mI; and glutamate/glutamine (Glx), reflecting the 
neuronal-glial neurotransmission   system. These measurements 
were acquired in radiologically   normal-appearing grey matter 
of the SSC.
Methods
Participants
Eleven subjects diagnosed with chronic LBP and eleven 
healthy age-matched subjects participated in the study. 
All participants signed informed consent in accordance 
with the Human Subjects Committee Review Board of 
the University of Kansas Medical Center. Subjects were 
included if they (i) had a medical diagnosis of chronic LBP 
(.3 months), (ii) experienced pain intensity of at least 4 
on a verbal numeric pain rating scale (range 0 = no pain; 
to 10 = the worst pain ever experienced), (iii) had no brain 
abnormalities on T2-weighted MRI, (iv) were aged between 
21 and 60 yrs, and (v) were able to understand simple 
instructions in English. Exclusion criteria were: (i) spinal 
cord compression, tumor, or infection, (ii) psychiatric 
diseases, (iii) current drug or alcohol abuse, or (iv) other 
neurological or neuromuscular patologies that might inter-
fere with our data. Five out of eleven patients were on pain 
therapy. Healthy controls, without neurological, psychiatric 
or pain disorders, MRI contraindications, and with normal 
T2-weighted images, were recruited.
Clinical measurements
Chronic LBP participants completed a physical examination 
comprised of lumbar range of motion and neurological 
examination. If the subjects did not present with motor 
nerve root compression or acute spinal pathology, they 
proceeded to complete self-reported questionnaires 
of pain and disability, such as the Short Form McGill 
Pain Questionnaire (SF-MPQ), Modified Oswestry 
Disability  Scale  (MODS),  Fear-Avoidance  Belief 
Questionnaire (FABQ), and Back Depression Inventory Scale   
(BDIS).
SF-MPQ,22 a reliable and valid scale,23 contains 15 pain 
items, 11 sensory and 4 affective. Each item is rated on an 
intensity scale with 0 = none, 1 = mild, 2 =   moderate, and 
3 = severe. The questionnaire also includes the present pain 
intensity (PPI) index and a visual analog scale (VAS, 0 = no 
pain, 10 = the worst pain ever experienced) for pain. The 
MODS, the gold standard test for assessing the disabling 
effects of lumbar spine pain, consists of 10 sections; each 
section is scored from 0 = minimum, 5 = maximum. Higher 
scores indicate greater   disability. The FABQ has items related 
to fear about physical (items 2–5) and work (items 6, 7, 
9–12, 15) activities and items not in either physical or work 
scale (items 1, 8, 13, 14, 16); each item is scored from 0 to 
6 with a higher number indicating increased fear of activity 
or work.24 The BDIS contains 21 items, each indicating a 
response from 0 = does not apply to 3 = applies very much 
to me, with the intensity of depression calculated based on 
the total score.25Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
145
Somatosensory cortex in low back pain
Magnetic resonance imaging (MRI) 
measurements
MRI assessments were performed on a 3 Tesla scanner 
(Siemens Medical Solutions, Erlangen, Germany) and total 
scan duration was about 30 minutes. A detailed description 
of these assessments has been reported previously.26
In brief, whole-brain 3D T1-weighted MRI was acquired 
to estimate brain tissue volume in spectroscopic voxels 
(MPRAGE; TR = 2300 ms; TE = 3 ms; FOV = 240 mm; 
matrix = 256 × 256; resolution = 1 × 1 × 1 mm3). An axial 
proton density/T2-weighted MRI (TR = 4800 ms; TE1/
TE2 = 18/106 ms; FOV = 240 mm; matrix size = 256 × 256; 
slice thickness = 5 mm, no gap) was acquired to exclude 
undiagnosed brain pathology in all participants.
One spectroscopic imaging slab (SIS) was selected in the 
frontal and parietal lobes sampling both gray matter (GM) 
and white matter (WM) of our region of interest, the SSC. 
The SIS was positioned according to the SSC anatomical 
landmarks27 applied on T2-weighted images (Brodmann 
area 3, 1, and 2; or post-central gyrus), and as posteriorly 
as possible to avoid the poorer magnetic field homogeneity 
of anterior regions that are not relevant to this study. To 
minimize the possible lipid artifact, eight outer voxel 
suppression bands (thickness = 30 mm) were prescribed 
around and above the SIS. SIS was acquired using a point-
resolved spectroscopy sequence (PRESS; TE = 30 ms; 
TR = 1500 ms; matrix size = 16 × 16; FOV = 160 mm2; 
slice thickness = 15 mm; in-plane resolution = 5 × 5 mm2; 
spectral width = 1200 Hz). Automated and then manual 
shimming was performed to achieve full-width at half 
maximum of ,20 Hz of the water signal from the entire 
excitation volume.
Metabolite concentrations were calculated using 
LCModel28 (a linear combination of model spectra using a 
basis set included in the package), using a radio-frequency coil 
loading factor. The T1-weighted images were segmented in 
GM, WM, and cerebrospinal fluid (SPM5, Welcome Depart-
ment of Cognitive Neurology, London, UK). As previously 
shown,26 by using custom-designed software (Matlab v7.1, 
2005), we overlaid the LCModel output and the segmented 
T1-weighted images on the SIS grid. This graphical interface 
is used to display spectra, brain fraction from segmentation, 
and the metabolite concentrations from LCModel in the 
spectroscopic voxels corresponding to cortical representa-
tion of the back in each SSC. Three spectroscopic voxels 
were selected in each SSC (see Figure 1) and each voxel 
contained GM . 75%, yielded a signal-to-noise ratio .10, 
and had   Cramer-Rao bounds ,20% for studied metabolites. 
Metabolite concentrations were brain tissue-corrected by nor-
malizing the LCModel output as follows: c = cLCModel*[1/
EFBT], where c is final concentration; cLCModel is metabolite 
concentration from LCModel output; and EFBT is the esti-
mated brain tissue (GM + WM) fraction. Finally, the corrected 
concentrations for all three voxels were averaged to provide a 
mean concentration (millimoles/kilogram wet weight, mM) 
for NAA, Cho, mI, and Glx in each SSC.
Statistical analysis
The analysis focused on four metabolites (NAA, Cho, mI, and 
Glx) in each SSC (left and right) and four clinical measures 
(pain, SF-MPQ; disability, MODS; fear, FABQ; depression, 
BDIS). Means and standard deviations were computed for 
each outcome variable.
The overall differences in metabolite concentrations 
between groups were analyzed by using independent 
sample t-test with unequal variance (2-tails). Individual 
metabolite differences between groups were also calculated 
with independent sample t-test (2 tails, unequal variance 
when indicated). Pearson correlation coefficient was used to 
examine correlations among metabolites within SSC (intra-
regional) and between left and right SSC (inter-regional). 
Distribution of original data (correlations strength) for 
RL
Central sulcus
Figure 1 1Proton magnetic resonance spectroscopy (h-MRS) analysis: Axial view 
of the spectroscopic imaging slab (rectangle) superimposed on T1-weighted image. 
Three spectroscopic voxels (squares) were selected in each somatosensory cortex 
(SSc). The arrows indicate the central sulcus.
Abbreviations: R, right; L, left.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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goodness of fit was assessed using the K-S test. Using a 
custom-designed routine (Matlab v7.1, 2005), the computed 
correlation coefficients were assigned to the following 
categories P , 0.004 (r = 1–0.77), 0.004 , P , 0.01 
(r = 0.76–0.70), 0.01 , P , 0.05 (r = 0.69–0.61), P . 0.05 
(r , 0.60). Similar categories were used for the negative 
correlations. The respective correlation coefficients were then 
transformed into gray (for positive) and blue (for negative) 
values to get a more straightforward visualization of the 
connectivity between different metabolites (see Figure 2). 
Pearson correlation coefficient was also used to study the 
correlations between metabolites and clinical measures. 
Differences were considered significant at P , 0.05 (SPSS 
18.0, SPSS Inc, Chicago, IL).
Results
Participants
LBP and healthy controls did not significantly differ with 
respect to age (mean ± SD, 33.6 ± 10.6 yrs vs 31.4 ± 13.9 yrs, 
P = 0.1). In the LBP group, the mean duration of symptoms 
was 10.6 ± 8.3 yrs, with an average pain intensity of 5.9 ± 
1.4 on VAS. Out of 11 subjects, seven reported radiating 
leg pain and four reported localized LBP. Five participants 
were on regular pain therapy (three on opiate analgesics, 
such as Oxycontin; two on anticonvulsant therapy, such as 
Neurotin, for pain control). In addition, three subjects took 
nonsteroidal anti-inflammatory drugs on an as-needed basis 
(average one medication per week). All but three subjects 
were carrying fulltime regular work responsibilities. The 
clinical characteristics of pain, disability, and depression are 
shown in Table 1. In summary, our subjects suffered long 
duration of pain symptoms, experienced moderate levels of 
pain intensity and disability, perceived high levels of fear of 
movement, and displayed mild depression.
Spectral quality
1H-MRS spectra with good signal-to-noise were obtained 
consistently from both LBP and controls (left SSC, 11.8 ± 
1.6 vs 11.8 ± 2.0, P = 0.9; right SSC, 12.4 ± 1.9 vs 12.3 ± 2.5, 
P = 0.9). Similar percentages of brain tissue within SSC were 
found between LBP and controls (left, 90.7 ± 3.9 vs 87.1 ± 
4.8, P = 0.1; right 86.2 ± 5.4 vs 82.8 ± 6.5, P = 0.2).
1H-MRS findings
Normal distribution for individual metabolites was verified 
with frequency and Q-Q plots, and the assumption of nor-
mal distribution was met. Overall metabolite concentrations 
were lower in both SSCs (left, -5.0%, t = 2.7, P = 0.07; 
right, -8.1%, t = 4.4, P = 0.02) in LBP compared to controls. 
Follow-up analysis showed significantly low NAA in the left 
SSC and low Cho in the right SSC (see Table 2). mI and Glx 
concentrations in either left or right SSC were not statistically 
different between the groups (Table 2).
The strength of correlations was normally distributed in 
both groups (P = 0.02 for each group). Lower correlations 
between all metabolites were detected in the right SSC in LBP 
(mean of correlation coefficients, 0.21 ± 0.19) than in controls 
(0.55 ± 0.14, t = 2.3, P = 0.007, Figure 2A). Although the 
mean correlation coefficient was not altered in the left SSC 
(t = 2.2, P = 0.1), individual correlations between NAA-mI, 
NAA-Cho and mI-Cho became lower and insignificant in 
LBP compared to controls (r = 0.26, P = 0.4 vs r = 0.83, 
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Figure 2 Metabolite connectivity pattern within (A, intra-regional) and between (B, inter-regional) somatosensory cortices (SScs) in controls (left panels) and chronic low 
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P = 0.001; r = 0.48, P = 0.14 vs r = -0.81, P = 0.03; r = -0.05, 
P = 0.87 vs r = 0.73, P = 0.01 respectively; Figure 2A). 
Further, higher and significant correlations between left mI 
and right Cho and between left and right mI were detected 
in LBP compared to controls (r = 0.61, P = 0.05 vs r = 0.17, 
P = 0.6; and r = 0.84, P = 0.00 vs r = 0.50, P = 0.1 respec-
tively; Figure 2B).
Pain duration was negatively correlated with NAA levels 
in both left (r = -0.62, P = 0.04) and right (r = -0.67, P = 0.02) 
SSC (Figure 3).
Although Glx concentrations were not significantly 
changed in LBP compared to controls (see Table 2), the right 
Glx was positively correlated with pain severity (as measured 
by SF-MPQ, r = 0.62, P = 0.04). No other correlations were 
found to be significant between SSC metabolites and clinical 
measures of disability, fear of movement, and depression.
Discussion
In the present study, two questions were investigated: (i) are 
cerebral metabolites altered in the SSC in chronic LBP? 
(ii) are these alterations related to clinical characteristics of 
pain? Our results suggest an overall decrease in metabolite 
levels in the right SSC and to a lesser degree in the left 
SSC, as well as altered intra- and inter-SSC metabolite cor-
relations in LBP patients compared to controls. In addition, 
certain SSC metabolites were correlated with pain duration 
and severity.
Our findings are consistent with previous LBP studies, 
in which metabolites were decreased overall in cortical 
regions involved in the affective-motivational aspect of 
pain.7–9 For instance, a decrease of 6.5% in total metabolite 
concentrations has been found in the DLPFC.9 We also 
found a similar overall metabolite decrease (6.5%) in 
each SSC in our patients. An anatomical substrate for this 
overall metabolite change could be the decrease in gray 
matter volume, as previously reported in these patients.21 
However, we corrected the metabolite concentrations for 
brain tissue fraction in each spectroscopic voxel and no 
significant differences in brain tissue were found between 
groups (see Results). Therefore, we can conclude that 
the metabolite alterations described here are not due 
to decreased grey matter volume in LBP. Finally, our 
overall SSC metabolite change might underlie the pain-
related functional SSC alterations, such as expansion and 
shift in the representation of low back in the SSC.19,20,29 
However, no studies have addressed whether the cortical 
functional reorganization in chronic LBP results from 
changes in brain chemistry. Such finding will improve 
our understanding of the neural substrates of chronic pain 
in humans.
Our finding of low NAA in the left SSC is also in 
agreement with previous studies. Low NAA have been 
consistently found in the DLPFC7,9 and anterior insula10 in 
Table 1 clinical scores (mean ± SD) in LBP participants
Clinical scores
SF-MPQ-sensory 15.1 ± 6.5
SF-MPQ-affective   2.5 ± 2.2
SF-MPQ-total 17.6 ± 8.0
SF-PPi   2.3 ± 1.0
MODS-total 17.3 ± 12.1
MODS-% disability 34.6 ± 24.0
FABQ-physical 13.5 ± 5.7
FABQ-work 11.6 ± 11.9
FABQ-total 37.5 ± 28.4
BDiS 15.1 ± 15.6
Abbreviations: LBP, low back pain; SF-MPQ, Short Form Mcgill Pain Questionnaire; 
MODS,  Modified  Oswestry  Disability  Scale;  FABQ,  Fear-Avoidance  Belief 
Questionnaire;  BDiS,  Back  Depression  inventory  Scale  (0  =  normal;  high  score 
indicates pain, disability, fear of movement or depression).
Table  2  Metabolite  concentrations  (mM)  in  left  and  right 
somatosensory cortices (SScs) in controls and LBP participants
NAA mI Cho Glx
Left SSC
controls 10.7 ± 2.0 4.7 ± 0.7 1.7 ± 0.2 12.7 ± 2.7
LBP 9.7 ± 0.5 4.6 ± 1.0 1.6 ± 0.6 11.8 ± 2.4
% -9.0 -1.5 -1.8 -7.5
P-value 0.001 0.84 0.88 0.42
Right SSC
controls 11.1 ± 1.7 5.2 ± 0.7 1.8 ± 0.2 11.9 ± 3.2
LBP 10.4 ± 1.3 5.0 ± 1.0 1.6 ± 0.3 10.8 ± 2.1
% -6.1 -4.2 -12.5 -9.3
P-value 0.30 0.60 0.038 0.30
Abbreviations: LBP, low back pain; nAA, n-acetylasparatate; mi, myo-inositol; 
cho, choline; glx, glutamate/glutamine.
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chronic LBP, as well as in other chronic pain conditions, 
such as pain following spinal cord injury.30,31 Recently, 
low NAA reported in the hippocampus of individuals 
who suffered from chronic widespread fibromyalgia 
pain32,33 was attributed to neuronal or axonal metabolic 
dysfunction. Therefore, the low NAA reported here might 
indicate altered neuronal mitochondrial metabolism, 
although other mechanisms such as pain medication or 
brain atrophy might contribute too. However, we do not 
attribute our results to medication use since we did not 
find metabolite changes in both hemispheres. Further, by 
excluding the five patients taking medications on a regular 
basis from analysis, in the remaining patients (n = 6), 
NAA was decreased by 11.9% in the left and 12% in the 
right SSC compared to controls. Finally, the presence of 
the relationships between NAA levels and pain duration 
(see Figure 3) provide support for NAA as a marker of 
neuronal mitochondrial depression as a result of long-term 
nociceptive input to the SSC.
We also report low Cho in the right SSC. Since Cho 
is thought to be involved in membrane synthesis and 
degradation, low Cho can be interpreted as an alteration 
in cell membrane integrity, as indicated by other authors 
in patients with fibromyalgia pain.32 Low Cho might also 
reflect changes in brain osmolarity.34 Since mI, another 
major brain osmolyte,35 was not significantly increased 
(P = 0.6), it is unlikely that low Cho was driven by 
hyperosmolarity, which would increase mI. Since Cho 
resonance is composed of choline, phosphocholine and 
glycerol-phosphocholine, a down-regulation of genes 
from enzymes responsible for metabolism of free choline, 
phosphocholine and phosphatidylcholine36 could explain 
the low Cho reported here. However, further studies are 
needed to determine the exact mechanisms underlying low 
Cho in chronic pain.
Although no  1H-MRS measurements have been 
reported in the SSC, one study reported no metabolite 
changes in the sensory-motor cortex in chronic LBP.9 The 
use of metabolite ratios to creatine9 can partially explain 
the discrepancy in the individual metabolite findings since 
creatine is not a reliable denominator.37 Indeed, we found 
significantly low creatine in the left SSC and a trend to 
low creatine in the right SSC in LBP compared to controls 
(6.8 ± 0.8 mM vs 7.5 ± 0.6 mM, P = 0.048; 10.8 ± 2.1 mM 
vs 11.9 ± 3.2, P = 0.3). Perhaps a more fundamental rea-
son for the discrepancy is that we studied only the SSC 
compared to the sensory-motor cortex examined in the 
previous study.9
In contrast to previous studies reporting low ACC Glx 
in LBP,10 we did not find significant Glx changes in the SSC 
in our LBP patients compared to controls (see Table 2). 
Although right Glx was not significantly altered in LBP, 
we found a positive relationship between Glx levels and 
pain severity. Since glutamate is related to chronic pain 
sensitization38 and it is the major component of Glx, we 
speculate that Glx might be involved in chronic pain-related 
SSC changes. However, further studies are required to 
confirm or reject this finding.
Since the SSC is involved in the sensory discrimination 
process of pain rather than the affective-motivational pain 
aspect, as expected, we did not find significant correlations 
between metabolite concentrations and the clinical measures 
of fear avoidance and depression.
The neuronal network exists through a close relationship 
among various metabolites at physiological levels; a relation-
ship that can be disturbed in pathologies. For example, the 
metabolite correlations within the DLPFC, ACC and thala-
mus were altered in chronic LBP.9 In agreement with these 
findings, we report weaker (or depression in) correlations 
between all metabolites in both SSC, predominantly in the 
right (see Figure 2A), in our patients than in the controls. 
Indeed, right SSC shows important changes of Cho, mI, and 
Glx concentrations (relative to controls, see Table 2), which 
might affect the correlation strengths between metabolites 
in this region. In contrast, stronger and significant correla-
tions were found across hemispheres, specifically between 
left mI and right mI and between left mI and right Cho (see 
Figure 2B). This inter-hemispheric increased metabolite con-
nectivity may be considered as an adaptive process, which 
might be necessary to preserve optimal SSC metabolism 
when metabolite concentrations are low. These findings high-
light the dynamic nature of changes not only in metabolite 
concentrations but also in their “communication” in chronic 
pain.
A limitation of our study is that we studied a small sample 
size (n = 11), and therefore we did not control for multiple 
comparisons, as in any pilot study. Despite this limitation, 
we observed changes in several brain metabolites as well as 
alterations in metabolite correlations that may potentially 
explain pain persistence.
Conclusion
In summary, we report the presence of SSC metabolite 
alterations, reflective of altered neuronal-glial interactions 
that correlate with clinical characteristics of pain. These 
changes may contribute to the persistent nature of pain Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
149
Somatosensory cortex in low back pain
without obvious pathology. Our results add to the current 
understanding of the neural substrate of cortical sensitization 
in chronic pain.
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